Bioventus Inc.

**Bioventus Inc.**

Bioventus is a medical device manufacturer focused on musculoskeletal and pain management therapies. The company operates across three primary business areas: pain treatments, surgical technologies, and orthopedic biologics. Its pain treatment portfolio consists of intra-articular injections and hyaluronic acid products for knee osteoarthritis, including Durolane, GELSYN-3, and SUPARTZ, along with peripheral nerve stimulation devices such as Stimrouter for chronic pain management. The company's surgical technologies segment includes ultrasonic surgical systems—Nexus, BoneScalpel, SonaStar, and SonicOne—designed for precision applications in orthopedic, neurosurgical, and soft tissue procedures. Bioventus also markets Exogen, an ultrasound bone stimulation system for fracture treatment and bone healing.

The orthopedic biologics segment encompasses bone graft substitutes and allograft products including Osteoamp, Signafuse, Purebone, and Reficio, which support bone fusion and reconstruction across orthopedic, neurosurgical, and reconstructive applications. Founded in 2011 and headquartered in Durham, North Carolina, Bioventus operates with approximately 950 full-time employees. The company maintains a presence in both U.S. and international markets, with distribution channels spanning orthopedic surgery, neurosurgery, and spinal procedures.